JW Life Science Corp
KRX:234080
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
JW Life Science Corp
Total Current Liabilities
JW Life Science Corp
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
JW Life Science Corp
KRX:234080
|
Total Current Liabilities
₩90.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Yuhan Corp
KRX:000100
|
Total Current Liabilities
₩733.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
7%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Current Liabilities
₩295.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Current Liabilities
₩605.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Current Liabilities
₩106.6B
|
CAGR 3-Years
41%
|
CAGR 5-Years
35%
|
CAGR 10-Years
17%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Total Current Liabilities
₩8.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
JW Life Science Corp
Glance View
JW Life Science Corp. manufactures intravenous fluids. The company is headquartered in Dangjin, Chungcheongnam-Do. The company went IPO on 2016-10-27. The firm is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The firm is also engaged in manufacture of total parenteral nutrition (TPN) products and others.
See Also
What is JW Life Science Corp's Total Current Liabilities?
Total Current Liabilities
90.1B
KRW
Based on the financial report for Dec 31, 2025, JW Life Science Corp's Total Current Liabilities amounts to 90.1B KRW.
What is JW Life Science Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
1%
Over the last year, the Total Current Liabilities growth was 12%. The average annual Total Current Liabilities growth rates for JW Life Science Corp have been 4% over the past three years , 5% over the past five years , and 1% over the past ten years .